{
    "clinical_study": {
        "@rank": "89058", 
        "acronym": "REVIEW", 
        "arm_group": {
            "arm_group_label": "Group 1"
        }, 
        "brief_summary": {
            "textblock": "Retrospective, non-interventional, observational multi-center field study. Patients\n      diagnosed with wet Age-related macular degeneration (wAMD) and having started treatment with\n      ranibizumab between January 1, 2009 and December 31, 2009 must be consecutively screened\n      and, if eligible, enrolled. Patients will be followed up at maximum until December 31, 2011.\n      Switch to any other Anti vascular endothelial growth factor (anti VEGF) treatment will be\n      documented. For each patient, demographics, medical history, administered treatments,\n      results of ocular and visual assessments and other tests (where available) will be\n      documented."
        }, 
        "brief_title": "Study to Assess the EffectiVeness of exIsting Anti-vascular Endothelial groWth Factor (Anti-VEGF) Treatment Regimens in Patients With Wet Age-related Macular Degeneration", 
        "completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "condition": "Macular Degeneration", 
        "condition_browse": {
            "mesh_term": "Macular Degeneration"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of wet Age-related Macular Degeneration\n\n          -  Start of anti-VEGF therapy with ranibizumab (Lucentis) between January 1, 2009 and\n             December 31, 2009\n\n          -  Informed consent form signed\n\n        Exclusion Criteria:\n\n        - Participation in an investigational study during anti-VEGF therapy (from start up to\n        December 31, 2011) that involved treatment with any drug or device"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients must have been diagnosed to suffer from wet AMD and must have started anti-VEGF\n        treatment with ranibizumab between January 1, 2009, and December 31, 2009"
            }
        }, 
        "enrollment": {
            "#text": "136", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01933152", 
            "org_study_id": "16378"
        }, 
        "intervention": {
            "arm_group_label": "Group 1", 
            "description": "Patients with wet AMD treated with ranibizumab as prescribed by physician", 
            "intervention_name": "Ranibizumab", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Mitogens", 
                "Endothelial Growth Factors", 
                "Bevacizumab"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "wAMD", 
            "anti-VEGF"
        ], 
        "lastchanged_date": "August 28, 2013", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Many Locations", 
                    "country": "Portugal"
                }
            }
        }, 
        "location_countries": {
            "country": "Portugal"
        }, 
        "number_of_groups": "1", 
        "official_title": "Review Study: A Retrospective Noninterventional Study to Assess the EffectiVeness of exIsting Anti-vascular Endothelial groWth Factor (Anti-VEGF) Treatment Regimens in Patients With Wet Age-related Macular Degeneration", 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Portugal: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Changes in visual acuity after start of Anti vascular endothelial growth factor (anti VEGF) therapy with ranibizumab, assessed by Early Treatment Diabetic Retinopathy (ETDRS) or Snellen chard", 
            "safety_issue": "No", 
            "time_frame": "Baseline and 24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01933152"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Demographic characteristics of patients included in the study (Age, Sex, Race)", 
                "safety_issue": "No", 
                "time_frame": "Baseline"
            }, 
            {
                "measure": "Mean time from first clinical presentation to diagnosis", 
                "safety_issue": "No", 
                "time_frame": "Baseline"
            }, 
            {
                "measure": "Mean time from diagnosis to treatment", 
                "safety_issue": "No", 
                "time_frame": "Time from diagnosis to treatment: Up to 24 months"
            }, 
            {
                "measure": "Mean time from diagnosis to end of follow-up", 
                "safety_issue": "No", 
                "time_frame": "Time from diagnosis to end of follow-up: up to 48 months"
            }, 
            {
                "measure": "Mean change of visual acuity, from diagnosis to end of follow-up, assessed by Early Treatment Diabetic Retinopathy (ETDRS) or Snellen chart", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 24 months"
            }, 
            {
                "measure": "Mean change of retinal thickness from diagnosis to end of follow-up, assessed by Optical Coherence Tomography (OCT)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 24 months"
            }, 
            {
                "measure": "Mean change of lesion size from diagnosis to end of follow-up, assessed by Fluorescein Angiography (FA)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 24 months"
            }, 
            {
                "measure": "Average number of treatments given from diagnosis to end of follow-up", 
                "safety_issue": "No", 
                "time_frame": "After 24 months"
            }
        ], 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "August 2013"
    }
}